{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T05:30:22Z","timestamp":1772861422011,"version":"3.50.1"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.ijcard.2024.131963","type":"journal-article","created":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T01:53:49Z","timestamp":1710208429000},"page":"131963","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Safety and efficacy of levosimendan in patients with cardiac amyloidosis"],"prefix":"10.1016","volume":"405","author":[{"given":"Alberto","family":"Aimo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Arzilli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Castiglione","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Morfino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgia","family":"Panichella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Passino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Vergaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Emdin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2024.131963_bb0005","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1161\/CIRCRESAHA.121.318187","article-title":"Pathophysiology and therapeutic approaches to cardiac amyloidosis","volume":"128","author":"Griffin","year":"2021","journal-title":"Circ. Res."},{"key":"10.1016\/j.ijcard.2024.131963_bb0010","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2024.131963_bb0015","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1002\/ejhf.2532","article-title":"Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta-analysis of screening studies","volume":"24","author":"Aimo","year":"2022","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ijcard.2024.131963_bb0020","doi-asserted-by":"crossref","first-page":"8552","DOI":"10.1038\/s41598-019-44912-x","article-title":"Predictors of mortality in light chain cardiac amyloidosis with heart failure","volume":"9","author":"Tahir","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ijcard.2024.131963_bb0025","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1161\/CIRCULATIONAHA.118.038169","article-title":"Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis","volume":"140","author":"Lane","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2024.131963_bb0030","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ijcard.2018.05.018","article-title":"Therapies for cardiac light chain amyloidosis: an update","volume":"271","author":"Aimo","year":"2018","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2024.131963_bb0035","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1093\/eurheartj\/ehz298","article-title":"Treatment of cardiac transthyretin amyloidosis: an update","volume":"40","author":"Emdin","year":"2019","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2024.131963_bb0040","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.amjcard.2023.07.023","article-title":"Adverse outcomes in hospitalizations for amyloid-related heart failure","volume":"203","author":"Appunni","year":"2023","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijcard.2024.131963_bb0045","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.amjcard.2021.02.035","article-title":"Causes of cardiovascular hospitalization and death in patients with transthyretin amyloid cardiomyopathy","volume":"148","author":"Miller","year":"2021","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijcard.2024.131963_bb0050","article-title":"Impact of levosimendan on efficacy and renal function in acute heart failure according to renal function: a perspective, multi-center, real-world registry","volume":"9","author":"Zhang","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.ijcard.2024.131963_bb0055","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1001\/jama.297.17.1883","article-title":"Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial","volume":"297","author":"Mebazaa","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2024.131963_bb0060","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0735-1097(00)00961-X","article-title":"Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure","volume":"36","author":"Nieminen","year":"2000","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2024.131963_bb0065","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1007\/s00059-018-4693-3","article-title":"Effect of levosimendan in patients with acute decompensated heart failure\u202f: a meta-analysis","volume":"44","author":"Zhou","year":"2019","journal-title":"Herz"},{"key":"10.1016\/j.ijcard.2024.131963_bb0070","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ejim.2020.06.037","article-title":"Safety and efficacy of levosimendan in patients with cardiac amyloidosis","volume":"80","author":"Aimo","year":"2020","journal-title":"Eur. J. Intern. Med."},{"key":"10.1016\/j.ijcard.2024.131963_bb0075","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.acvd.2018.03.004","article-title":"Outcome of patients with cardiac amyloidosis admitted to an intensive care unit for acute heart failure","volume":"111","author":"d\u2019Humieres","year":"2018","journal-title":"Arch. Cardiovasc. Dis."},{"key":"10.1016\/j.ijcard.2024.131963_bb0080","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/13506129.2017.1372412","article-title":"Successful use of palliative inotrope therapy in end-stage cardiac ATTR amyloidosis","volume":"24","author":"Panhwar","year":"2017","journal-title":"Amyloid"},{"key":"10.1016\/j.ijcard.2024.131963_bb0085","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2024.131963_bb0090","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1093\/eurheartj\/ehs104","article-title":"ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology","volume":"33","author":"McMurray","year":"2012","journal-title":"Eur. Heart J."},{"issue":"37","key":"10.1016\/j.ijcard.2024.131963_bb0095","first-page":"2129","article-title":"ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)","volume":"2016","author":"Ponikowski","year":"2016"},{"key":"10.1016\/j.ijcard.2024.131963_bb0100","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.jacc.2022.01.036","article-title":"Critical comparison of documents from scientific societies on cardiac amyloidosis: JACC state-of-the-art review","volume":"79","author":"Rapezzi","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2024.131963_bb0110","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1002\/ehf2.14337","article-title":"Patients with cardiac amyloidosis are at a greater risk of mortality and hospital readmission after acute heart failure","volume":"10","author":"Berthelot","year":"2023","journal-title":"ESC Heart Fail."},{"key":"10.1016\/j.ijcard.2024.131963_bb0115","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1161\/01.CIR.102.18.2222","article-title":"Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure","volume":"102","author":"Slawsky","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2024.131963_bb0120","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1001\/jama.297.17.1883","article-title":"Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial","volume":"297","author":"Mebazaa","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2024.131963_bb0125","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejheart.2006.04.012","article-title":"Duration of the haemodynamic action of a 24-h infusion of levosimendan in patients with congestive heart failure","volume":"9","author":"Lilleberg","year":"2007","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ijcard.2024.131963_bb0130","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/ejhf.2113","article-title":"Use of biomarkers to diagnose and manage cardiac amyloidosis","volume":"23","author":"Castiglione","year":"2021","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ijcard.2024.131963_bb0135","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1161\/CIRCULATIONAHA.118.038169","article-title":"Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis","volume":"140","author":"Lane","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2024.131963_bb0140","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/ejhf.9","article-title":"Levosimendan improves renal function in acute decompensated heart failure: possible underlying mechanisms","volume":"16","author":"Fedele","year":"2014","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ijcard.2024.131963_bb0145","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0233176","article-title":"Levosimendan reduces segmental pulmonary vascular resistance in isolated perfused rat lungs and relaxes human pulmonary vessels","volume":"15","author":"Rieg","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.ijcard.2024.131963_bb0150","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S0140-6736(02)09455-2","article-title":"Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial","volume":"360","author":"Follath","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2024.131963_bb0155","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1080\/13506129.2021.1966624","article-title":"Patients with cardiac amyloidosis have a greater neurohormonal activation than those with non-amyloidotic heart failure","volume":"28","author":"Vergaro","year":"2021","journal-title":"Amyloid"},{"key":"10.1016\/j.ijcard.2024.131963_bb0160","doi-asserted-by":"crossref","first-page":"4868","DOI":"10.3390\/jcm10214868","article-title":"Prognostic value of N-terminal pro-brain natriuretic peptide and high-sensitivity troponin T levels in the natural history of transthyretin amyloid cardiomyopathy and their evolution after tafamidis treatment","volume":"10","author":"Oghina","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ijcard.2024.131963_bb0165","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1200\/JCO.22.00643","article-title":"Graded cardiac response criteria for patients with systemic light chain amyloidosis","volume":"41","author":"Muchtar","year":"2023","journal-title":"J. Clin. Oncol."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527324005138?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527324005138?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T22:57:29Z","timestamp":1713999449000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527324005138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":32,"alternative-id":["S0167527324005138"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2024.131963","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of levosimendan in patients with cardiac amyloidosis","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2024.131963","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"131963"}}